Physicians Realty Trust - Quarter Report: 2023 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-36007
PHYSICIANS REALTY TRUST
(Exact Name of Registrant as Specified in its Charter)
| Maryland | 46-2519850 | ||||||||||
| (State of Organization) | (IRS Employer Identification No.) | ||||||||||
| 309 N. Water Street, Suite 500 | 53202 | ||||||||||
| Milwaukee, | Wisconsin | ||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | ||||||||||
(414) 367-5600
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
| Common stock, $0.01 par value per share | DOC | New York Stock Exchange | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The number of Physicians Realty Trust’s common shares outstanding as of April 26, 2023 was 238,398,561.
PHYSICIANS REALTY TRUST
Quarterly Report on Form 10-Q
for the Quarter Ended March 31, 2023
Table of Contents
| Page Number | ||||||||
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements within the meaning of the federal securities laws. In particular, statements pertaining to our capital resources, property performance, and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics, and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “expect,” “outlook,” “continue,” “project,” “may,” “will,” “should,” “seek,” “approximately,” “intend,” “plan,” “pro forma,” “estimate,” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, expectations, or intentions.
These forward-looking statements reflect the views of our management regarding current expectations and projections about future events and are based on currently available information. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data, or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:
•general economic conditions, including inflation and recession;
•changes in our business or strategy;
•our ability to operate as a public company;
•adverse economic or real estate developments, either nationally or in the markets where our properties are located;
•our geographic concentration in Texas may cause us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions;
•our concentration of investment in health care properties;
•the disruption of our business and the compromise of confidential information resulting from cybersecurity attacks, breaches, and other incidents;
•any adverse effects to the business, financial position or results of operations of CommonSpirit Health (“CommonSpirit”), or one or more of the CommonSpirit-affiliated tenants, that impact the ability of CommonSpirit-affiliated tenants to pay us rent;
•the degree and nature of our competition;
•competition for investment opportunities;
•difficulties in identifying health care properties to acquire and completing acquisitions;
•the unknown duration and economic, operational, and financial impacts of the global outbreak of a novel strain of the coronavirus and any variants that have emerged or that may emerge in the future, (the “COVID-19 pandemic”) and the actions taken by governmental authorities or others in connection with the COVID-19 pandemic will have on the Company’s business;
•changes in health care laws or government reimbursement rates;
•decreased rental rates or increased vacancy rates;
•defaults on or non-renewal of leases by tenants;
•the potential impact of severe weather events and climate change;
1
•our failure to generate sufficient cash flows to service, pay down, or refinance our indebtedness or make distributions on our common shares;
•fluctuations and increases in interest rates and operating costs;
•the availability, terms, and issuance of debt and equity capital, including our unsecured revolving credit facility;
•general volatility of the market price of our common shares;
•our dependence upon key personnel whose continued service is not guaranteed;
•our ability to identify, hire, and retain highly qualified personnel in the future;
•the impact of our investments in joint ventures we have made and may make in the future;
•the financial condition and liquidity of, or disputes with, any joint venture and development partners with whom we may make co-investments in the future;
•changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates, taxation of real estate investment trusts (“REITs”), and similar matters;
•our failure to maintain our qualification as a REIT for U.S. federal income tax purposes;
•limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes;
•changes in accounting principles generally accepted in the United States (“GAAP”);
•lack of or insufficient amounts of insurance;
•other factors affecting the real estate industry generally; and
•other factors that may materially adversely affect us, or the per share trading price of our common shares, including:
•the number of our common shares available for future issuance or sale;
•our issuance of equity securities or the perception that such issuance might occur;
•future debt;
•failure of securities analysts to publish research or reports about us or our industry; and
•securities analysts’ downgrade of our common shares or the health care-related real estate sector.
While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events, or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements. For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (the “Commission”) on February 24, 2023 (the “2022 Annual Report”).
As used in this report, unless the context otherwise requires, references to “we,” “us,” “our,” and the “Company” refer to Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership and the consolidated subsidiary of the Trust through which we conduct our business.
2
PART I. Financial Information
Item 1. Financial Statements
Physicians Realty Trust
Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31, 2023 | December 31, 2022 | ||||||||||
| (unaudited) | |||||||||||
| ASSETS | |||||||||||
| Investment properties: | |||||||||||
| Land and improvements | $ | 242,107 | $ | 241,559 | |||||||
| Building and improvements | 4,678,995 | 4,674,011 | |||||||||
| Tenant improvements | 96,527 | 92,906 | |||||||||
| Acquired lease intangibles | 505,074 | 505,335 | |||||||||
| 5,522,703 | 5,513,811 | ||||||||||
| Accumulated depreciation | (1,043,884) | (996,888) | |||||||||
| Net real estate property | 4,478,819 | 4,516,923 | |||||||||
| Right-of-use lease assets, net | 230,254 | 231,225 | |||||||||
| Real estate loans receivable, net | 115,764 | 104,973 | |||||||||
| Investments in unconsolidated entities | 75,086 | 77,716 | |||||||||
| Net real estate investments | 4,899,923 | 4,930,837 | |||||||||
| Cash and cash equivalents | 3,364 | 7,730 | |||||||||
| Tenant receivables, net | 10,830 | 11,503 | |||||||||
| Other assets | 147,050 | 146,807 | |||||||||
| Total assets | $ | 5,061,167 | $ | 5,096,877 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Liabilities: | |||||||||||
| Credit facility | $ | 147,762 | $ | 188,328 | |||||||
| Notes payable | 1,450,798 | 1,465,437 | |||||||||
| Mortgage debt | 164,130 | 164,352 | |||||||||
| Accounts payable | 3,343 | 4,391 | |||||||||
| Dividends and distributions payable | 59,824 | 60,148 | |||||||||
| Accrued expenses and other liabilities | 85,007 | 87,720 | |||||||||
| Lease liabilities | 104,856 | 105,011 | |||||||||
| Acquired lease intangibles, net | 23,796 | 24,381 | |||||||||
| Total liabilities | 2,039,516 | 2,099,768 | |||||||||
| Redeemable noncontrolling interests - partially owned properties | 3,193 | 3,258 | |||||||||
| Equity: | |||||||||||
Common shares, $0.01 par value, 500,000,000 common shares authorized, 238,395,869 and 233,292,030 common shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 2,384 | 2,333 | |||||||||
| Additional paid-in capital | 3,810,504 | 3,743,876 | |||||||||
| Accumulated deficit | (926,790) | (881,672) | |||||||||
| Accumulated other comprehensive income | 4,162 | 5,183 | |||||||||
| Total shareholders’ equity | 2,890,260 | 2,869,720 | |||||||||
| Noncontrolling interests: | |||||||||||
| Operating Partnership | 119,187 | 123,015 | |||||||||
| Partially owned properties | 9,011 | 1,116 | |||||||||
| Total noncontrolling interests | 128,198 | 124,131 | |||||||||
| Total equity | 3,018,458 | 2,993,851 | |||||||||
| Total liabilities and equity | $ | 5,061,167 | $ | 5,096,877 | |||||||
The accompanying notes are an integral part of these consolidated financial statements.
3
Physicians Realty Trust
Consolidated Statements of Income
(In thousands, except share and per share data) (Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Revenues: | |||||||||||
| Rental and related revenues | $ | 131,398 | $ | 127,791 | |||||||
| Interest income on real estate loans and other | 2,946 | 2,599 | |||||||||
| Total revenues | 134,344 | 130,390 | |||||||||
| Expenses: | |||||||||||
| Interest expense | 19,153 | 16,823 | |||||||||
| General and administrative | 11,200 | 10,293 | |||||||||
| Operating expenses | 45,394 | 41,752 | |||||||||
| Depreciation and amortization | 47,677 | 47,260 | |||||||||
| Total expenses | 123,424 | 116,128 | |||||||||
| Income before equity in loss of unconsolidated entities and gain (loss) on sale of investment properties, net: | 10,920 | 14,262 | |||||||||
| Equity in loss of unconsolidated entities | (264) | (166) | |||||||||
| Gain (loss) on sale of investment properties, net | 13 | (153) | |||||||||
| Net income | 10,669 | 13,943 | |||||||||
| Net income attributable to noncontrolling interests: | |||||||||||
| Operating Partnership | (423) | (692) | |||||||||
| Partially owned properties (1) | (44) | (159) | |||||||||
| Net income attributable to common shareholders | $ | 10,202 | $ | 13,092 | |||||||
| Net income per share: | |||||||||||
| Basic | $ | 0.04 | $ | 0.06 | |||||||
| Diluted | $ | 0.04 | $ | 0.06 | |||||||
| Weighted average common shares: | |||||||||||
| Basic | 237,484,043 | 225,069,208 | |||||||||
| Diluted | 248,756,672 | 238,340,243 | |||||||||
| Dividends and distributions declared per common share | $ | 0.23 | $ | 0.23 | |||||||
(1)Includes amounts attributable to redeemable noncontrolling interests.
The accompanying notes are an integral part of these consolidated financial statements.
4
Physicians Realty Trust
Consolidated Statements of Comprehensive Income
(In thousands) (Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Other comprehensive income: | |||||||||||
| Change in fair value of interest rate swap agreements, net | (1,021) | 1,379 | |||||||||
| Total other comprehensive (loss) income | (1,021) | 1,379 | |||||||||
| Comprehensive income | 9,648 | 15,322 | |||||||||
| Comprehensive income attributable to noncontrolling interests - Operating Partnership | (383) | (761) | |||||||||
| Comprehensive income attributable to noncontrolling interests - partially owned properties | (44) | (159) | |||||||||
| Comprehensive income attributable to common shareholders | $ | 9,221 | $ | 14,402 | |||||||
The accompanying notes are an integral part of these consolidated financial statements.
5
Physicians Realty Trust
Consolidated Statements of Equity
(In thousands) (Unaudited)
| Par Value | Additional Paid in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity | Operating Partnership Noncontrolling Interest | Partially Owned Properties Noncontrolling Interest | Total Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2022 | $ | 2,333 | $ | 3,743,876 | $ | (881,672) | $ | 5,183 | $ | 2,869,720 | $ | 123,015 | $ | 1,116 | $ | 124,131 | $ | 2,993,851 | |||||||||||||||||||||||||||||||||||
| Net proceeds from sale of common shares | 44 | 65,769 | — | — | 65,813 | — | — | — | 65,813 | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted share award grants, net | 5 | (1,127) | (408) | — | (1,530) | — | — | — | (1,530) | ||||||||||||||||||||||||||||||||||||||||||||
| Conversion of OP Units | 2 | 2,417 | — | — | 2,419 | (2,419) | — | (2,419) | — | ||||||||||||||||||||||||||||||||||||||||||||
| Dividends/distributions declared | — | — | (54,912) | — | (54,912) | (2,263) | — | (2,263) | (57,175) | ||||||||||||||||||||||||||||||||||||||||||||
| Contributions | — | — | — | — | — | — | 7,884 | 7,884 | 7,884 | ||||||||||||||||||||||||||||||||||||||||||||
| Distributions | — | — | — | — | — | — | (53) | (53) | (53) | ||||||||||||||||||||||||||||||||||||||||||||
| Change in fair value of interest rate swap agreement | — | — | — | (1,021) | (1,021) | — | — | — | (1,021) | ||||||||||||||||||||||||||||||||||||||||||||
| Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | (431) | — | — | (431) | 431 | — | 431 | — | ||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | 10,202 | — | 10,202 | 423 | 64 | 487 | 10,689 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2023 | $ | 2,384 | $ | 3,810,504 | $ | (926,790) | $ | 4,162 | $ | 2,890,260 | $ | 119,187 | $ | 9,011 | $ | 128,198 | $ | 3,018,458 | |||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
6
Physicians Realty Trust
Consolidated Statements of Equity
(In thousands) (Unaudited)
| Par Value | Additional Paid in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity | Operating Partnership Noncontrolling Interest | Partially Owned Properties Noncontrolling Interest | Total Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2021 | $ | 2,247 | $ | 3,610,954 | $ | (776,001) | $ | (892) | $ | 2,836,308 | $ | 150,241 | $ | 484 | $ | 150,725 | $ | 2,987,033 | |||||||||||||||||||||||||||||||||||
| Net proceeds from sale of common shares | 3 | 5,029 | — | — | 5,032 | — | — | — | 5,032 | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted share award grants, net | 3 | 118 | (421) | — | (300) | — | — | — | (300) | ||||||||||||||||||||||||||||||||||||||||||||
| Purchase of OP Units | — | — | — | — | — | (184) | — | (184) | (184) | ||||||||||||||||||||||||||||||||||||||||||||
| Dividends/distributions declared | — | — | (51,879) | — | (51,879) | (2,740) | — | (2,740) | (54,619) | ||||||||||||||||||||||||||||||||||||||||||||
| Contributions | — | — | — | — | — | — | 569 | 569 | 569 | ||||||||||||||||||||||||||||||||||||||||||||
| Distributions | — | — | — | — | — | — | (55) | (55) | (55) | ||||||||||||||||||||||||||||||||||||||||||||
| Change in market value of Redeemable Noncontrolling Interest in partially owned properties | — | — | 717 | — | 717 | — | — | — | 717 | ||||||||||||||||||||||||||||||||||||||||||||
| Change in fair value of interest rate swap agreement | — | — | — | 1,379 | 1,379 | — | — | — | 1,379 | ||||||||||||||||||||||||||||||||||||||||||||
| Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | (217) | — | — | (217) | 217 | — | 217 | — | ||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | 13,092 | — | 13,092 | 692 | 82 | 774 | 13,866 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2022 | $ | 2,253 | $ | 3,615,884 | $ | (814,492) | $ | 487 | $ | 2,804,132 | $ | 148,226 | $ | 1,080 | $ | 149,306 | $ | 2,953,438 | |||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
7
Physicians Realty Trust
Consolidated Statements of Cash Flows
(In thousands) (Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
| Depreciation and amortization | 47,677 | 47,260 | |||||||||
| Amortization of deferred financing costs | 569 | 579 | |||||||||
| Amortization of lease inducements and above/below-market lease intangibles | 1,364 | 1,575 | |||||||||
| Straight-line rental revenue, net | (1,235) | (2,154) | |||||||||
| Amortization of discount on unsecured senior notes | 272 | 262 | |||||||||
| Amortization of above market assumed debt | — | (10) | |||||||||
| (Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
| Equity in loss of unconsolidated entities | 264 | 166 | |||||||||
| Distributions from unconsolidated entities | 1,906 | 2,002 | |||||||||
| Provision for bad debts | 281 | 87 | |||||||||
| Non-cash share compensation | 4,667 | 4,253 | |||||||||
| Change in operating assets and liabilities: | |||||||||||
| Tenant receivables | 567 | (791) | |||||||||
| Other assets | 536 | (266) | |||||||||
| Accounts payable | (1,048) | (5,252) | |||||||||
| Accrued expenses and other liabilities | (2,757) | (7,272) | |||||||||
| Net cash provided by operating activities | 63,719 | 54,535 | |||||||||
| Cash Flows from Investing Activities: | |||||||||||
| Proceeds from sale of investment properties | 2,553 | 1,804 | |||||||||
| Acquisition of investment properties, net | (2,650) | (10) | |||||||||
| Investment in unconsolidated entities | (180) | (5,045) | |||||||||
| Development of real estate | (953) | — | |||||||||
| Escrowed cash - acquisition deposits/earnest deposits | — | 90 | |||||||||
| Capital expenditures on investment properties | (8,400) | (5,491) | |||||||||
| Investment in real estate loans receivable | (10,956) | (904) | |||||||||
| Repayment of real estate loans receivable | — | 22,441 | |||||||||
| Leasing commissions | (782) | (704) | |||||||||
| Lease inducements | (400) | — | |||||||||
| Net cash (used in) provided by investing activities | (21,768) | 12,181 | |||||||||
| Cash Flows from Financing Activities: | |||||||||||
| Net proceeds from sale of common shares | 65,813 | 5,032 | |||||||||
| Proceeds from credit facility borrowings | 55,000 | 64,000 | |||||||||
| Repayment of credit facility borrowings | (96,000) | (83,000) | |||||||||
| Repayment of senior unsecured notes | (15,000) | — | |||||||||
| Principal payments on mortgage debt | (253) | (420) | |||||||||
| Debt issuance costs | (14) | (10) | |||||||||
| Dividends paid - shareholders | (55,643) | (52,858) | |||||||||
| Distributions to noncontrolling interests - Operating Partnership | (2,264) | (2,739) | |||||||||
| Contributions from noncontrolling interest | 7,884 | 569 | |||||||||
| Distributions to noncontrolling interests - partially owned properties | (98) | (161) | |||||||||
| Payments of employee taxes for withheld stock-based compensation shares | (5,742) | (4,092) | |||||||||
| Purchase of OP Units | — | (184) | |||||||||
| Net cash used in financing activities | (46,317) | (73,863) | |||||||||
| Net decrease in cash and cash equivalents | (4,366) | (7,147) | |||||||||
| Cash and cash equivalents, beginning of period | 7,730 | 9,876 | |||||||||
| Cash and cash equivalents, end of period | $ | 3,364 | $ | 2,729 | |||||||
| Supplemental disclosure of cash flow information—interest paid during the period | $ | 25,176 | $ | 23,123 | |||||||
| Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements | $ | (1,021) | $ | 1,379 | |||||||
| Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property | $ | — | $ | 3,000 | |||||||
The accompanying notes are an integral part of these consolidated financial statements.
8
Physicians Realty Trust
Notes to Consolidated Financial Statements
Unless otherwise indicated or unless the context requires otherwise, the use of the words “we,” “us,” “our,” and the “Company,” refer to Physicians Realty Trust, together with its consolidated subsidiaries, including Physicians Realty L.P.
Note 1. Organization and Business
Physicians Realty Trust (the “Trust” or the “Company”) was organized in the state of Maryland on April 9, 2013. As of March 31, 2023, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share. The Trust filed a Registration Statement on Form S-11 with the Commission with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013.
The Trust contributed the net proceeds from the IPO to Physicians Realty L.P, a Delaware limited partnership (the “Operating Partnership”), and is the sole general partner of the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.
The Trust is a self-managed REIT formed primarily to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems.
ATM Program
In May 2021, the Trust and the Operating Partnership entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., and Raymond James & Associates, Inc. in their capacity as agents for the Company and/or forward sellers and Stifel, Nicolaus & Company, Incorporated in its capacity as sales agent for the Company (collectively, the “Agents”) and Bank of Montreal, Credit Agricole Corporate and Investments Bank, KeyBanc Capital Markets Inc., and Raymond James & Associates, Inc. as forward purchasers for the Company (the “Forward Purchasers”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million through the Agents (the “ATM Program”). The Sales Agreement contemplates that, in addition to the issuance and sale of the Trust’s common shares through the Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of the Forward Purchasers.
During the quarterly period ended March 31, 2023, the Trust sold 4,400,000 common shares pursuant to the ATM Program, at a weighted average price of $15.10 per share, resulting in total net proceeds of approximately $65.8 million. As of March 31, 2023, the Trust had $158.6 million remaining available under the ATM Program.
Note 2. Summary of Significant Accounting Policies
The accompanying unaudited consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods ended March 31, 2023 and 2022 pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements included in the Trust’s 2022 Annual Report. The Company has consistently applied its accounting policies to all periods presented in these consolidated financial statements.
Noncontrolling Interests
The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.
Operating Partnership: Noncontrolling interests in the Company include OP Units held by other investors. Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units
9
changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.
As of March 31, 2023, the Trust held a 96.0% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.
Partially Owned Properties: The Trust reflects noncontrolling interests in partially owned properties on the consolidated balance sheets for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.
Redeemable Noncontrolling Interests - Partially Owned Properties
In connection with the Company’s acquisitions of the medical office building, ambulatory surgery center, and hospital located on the Great Falls Hospital campus in Great Falls, Montana, physicians affiliated with the sellers retained non-controlling interests which were, at the holders’ option, able to be redeemed at any time after May 1, 2023. Due to the redemption provision, which was outside of the control of the Trust, the Trust classified the investment in the mezzanine section of its consolidated balance sheets. On July 14, 2022, the Company disposed of these three properties and removed the related redeemable noncontrolling interests from its consolidated balance sheets.
Through a consolidated joint venture with MedProperties Realty Advisors, LLC (“MedProperties”), the Company acquired Calko Medical Center in Brooklyn, New York. As part of the joint venture, MedProperties can redeem its interest, at its option, at any time after September 9, 2025. Due to the redemption provision, which is outside of the control of the Company, the Company classifies the noncontrolling interests in the mezzanine section of its consolidated balance sheets. The Company records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.
Dividends and Distributions
On March 17, 2023, the Trust announced that its Board of Trustees authorized, and the Trust declared, a cash dividend of $0.23 per common share for the quarter ended March 31, 2023. The dividend was paid on April 18, 2023 to common shareholders and holders of record of partnership interests of the Operating Partnership (“OP Units”) as of the close of business on April 4, 2023.
Tax Status of Dividends and Distributions
The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.
Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units).
The Company has elected taxable REIT subsidiary (“TRS”) status for certain of its corporate subsidiaries and, as a result, these entities will incur both federal and state income taxes on any taxable income of such entities after consideration of any net operating losses. To date, these income taxes have been de minimis.
Real Estate Loans Receivable, Net
Real estate loans receivable consists of eight mezzanine loans, six term loans, and two construction loans as of March 31, 2023. Generally, each mezzanine loan is collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, each term loan is secured by a mortgage on a related medical office building, and construction loans are secured by mortgages on the land and the improvements as constructed. The reserve for loan losses was $0.2 million as of March 31, 2023.
10
Rental and Related Revenues
Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants are included in other assets and were approximately $102.9 million and $101.3 million as of March 31, 2023 and December 31, 2022, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable.
In accordance with ASC 842, Leases, Topic 842, if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was $0.4 million for the three months ended March 31, 2023 and $0.1 million for the three months ended March 31, 2022.
Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as these costs are incurred by the Company and reimbursed by the tenants. We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses and we do not recognize expense recoveries.
New Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (“LIBOR”), which has been discontinued at the end of 2021. The amendments in this update may be applied through December 31, 2024. The Company will continue to use published LIBOR rates through June of 2023, or until all transactions referencing LIBOR have been amended.
On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Third Amended and Restated Credit Agreement to update the benchmark provisions to replace LIBOR with the Secured Overnight Financing Rate (“SOFR”), as the reference rate for the purpose of calculating interest under the agreement. In connection with amending the unsecured credit agreement, we also amended our fixed interest rate swap agreement to update reference rate from LIBOR to SOFR. As a result, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients maintains the presentation of derivatives consistent with past presentation. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
Note 3. Investment and Disposition Activity
During the three months ended March 31, 2023, the Company executed contractual commitments related to a $40.5 million development project, with quarterly costs of $1.0 million, completed the acquisition of one medical condominium unit for an investment of $1.3 million and one parcel of land adjacent to one of its medical office facilities for an investment of $0.8 million, and paid $0.3 million of additional purchase consideration under two earn-out agreements. The Company also closed on a $35.8 million construction loan, funding $4.1 million to date, and funded one term loan for $5.4 million, $1.0 million of previous construction loan commitments, and $0.5 million of previous term loan commitments. Additionally, the Company invested $0.2 million in funds managed by a real estate technology private equity fund. Investment activity totaled approximately $14.4 million during the three months ended March 31, 2023. As part of these investments, the Company incurred approximately $0.2 million of capitalized costs.
11
The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed in connection with the acquisition of the medical condominium unit, a parcel of land adjacent to one of our medical office facilities, and two earn-out agreements, as well as follow-on capitalized costs during the three months ended March 31, 2023, which the Company determined using Level 2 and Level 3 inputs (in thousands):
| Land | $ | 1,356 | |||
| Building and improvements | 1,294 | ||||
| Cash used in acquisition of investment property | $ | 2,650 | |||
Dispositions
During the three months ended March 31, 2023, the Company sold one medical facility for approximately $2.6 million, realizing an insignificant gain.
Note 4. Intangibles
The following is a summary of the carrying amount of intangible assets and liabilities as of March 31, 2023 and December 31, 2022 (in thousands):
| March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||
| Cost | Accumulated Amortization | Net | Cost | Accumulated Amortization | Net | ||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||
| In-place leases | $ | 445,322 | $ | (251,995) | $ | 193,327 | $ | 445,583 | $ | (241,643) | $ | 203,940 | |||||||||||||||||||||||
| Above-market leases | $ | 59,752 | $ | (31,511) | $ | 28,241 | $ | 59,752 | $ | (30,096) | $ | 29,656 | |||||||||||||||||||||||
| Liabilities | |||||||||||||||||||||||||||||||||||
| Below-market leases | $ | 36,409 | $ | (12,613) | $ | 23,796 | $ | 37,002 | $ | (12,621) | $ | 24,381 | |||||||||||||||||||||||
The following is a summary of acquired lease intangible amortization for the three months ended March 31, 2023 and 2022 (in thousands):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Amortization expense related to in-place leases | $ | 10,612 | $ | 11,040 | |||||||
| Decrease in rental income related to above-market leases | 1,415 | 1,502 | |||||||||
| Increase in rental income related to below-market leases | 586 | 459 | |||||||||
Future aggregate net amortization of acquired lease intangibles as of March 31, 2023, is as follows (in thousands):
| Net Decrease (Increase) in Revenue | Net Increase in Expenses | ||||||||||
| 2023 | $ | 2,361 | $ | 30,004 | |||||||
| 2024 | 2,929 | 34,718 | |||||||||
| 2025 | 2,357 | 29,208 | |||||||||
| 2026 | 1,203 | 23,095 | |||||||||
| 2027 | 1,036 | 20,173 | |||||||||
| Thereafter | (5,441) | 56,129 | |||||||||
| Total | $ | 4,445 | $ | 193,327 | |||||||
As of March 31, 2023, the weighted average remaining amortization period is 7 years for in-place and above-market lease intangibles assets and 15 years for below-market lease intangibles.
12
Note 5. Other Assets
Other assets consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
| March 31, 2023 | December 31, 2022 | ||||||||||
| Straight line rent receivable, net | $ | 102,856 | $ | 101,306 | |||||||
| Leasing commissions, net | 13,449 | 13,231 | |||||||||
| Prepaid expenses | 10,657 | 11,009 | |||||||||
| Lease inducements, net | 8,065 | 7,894 | |||||||||
| Interest rate swap | 1,645 | 2,045 | |||||||||
| Escrows | 1,352 | 1,565 | |||||||||
| Notes receivable, net | 367 | 370 | |||||||||
| Other | 8,659 | 9,387 | |||||||||
| Total | $ | 147,050 | $ | 146,807 | |||||||
Note 6. Debt
The following is a summary of debt as of March 31, 2023 and December 31, 2022 (in thousands):
| March 31, 2023 | December 31, 2022 | ||||||||||
| Fixed interest mortgage notes (1) | $ | 59,641 | $ | 59,776 | |||||||
| Variable interest mortgage notes (2) | 105,035 | 105,153 | |||||||||
| Total mortgage debt | 164,676 | 164,929 | |||||||||
$1.0 billion unsecured revolving credit facility due September 2025 (3) | 152,000 | 193,000 | |||||||||
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 | 400,000 | 400,000 | |||||||||
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 | 350,000 | 350,000 | |||||||||
$500 million senior unsecured notes bearing fixed interest of 2.625%, due November 2031 | 500,000 | 500,000 | |||||||||
$135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031 | 135,000 | 150,000 | |||||||||
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | 75,000 | 75,000 | |||||||||
| Total principal | 1,776,676 | 1,832,929 | |||||||||
| Unamortized deferred financing costs | (6,899) | (7,453) | |||||||||
| Unamortized discounts | (7,087) | (7,359) | |||||||||
| Total debt | $ | 1,762,690 | $ | 1,818,117 | |||||||
(1)As of March 31, 2023, fixed interest mortgage notes bear interest from 3.25% to 4.63%, due in 2024, with a weighted average interest rate of 3.80%. As of December 31, 2022, fixed interest mortgage notes bear interest from 3.33% to 4.63%, due in 2024, with a weighted average interest rate of 3.85%. The notes are collateralized by two properties with a net book value of $93.1 million as of March 31, 2023 and two properties with a net book value of $94.9 million as of December 31, 2022. One mortgage bears interest at LIBOR + 1.90% and the Trust entered into a pay-fixed receive-variable interest rate swap, fixing the variable component at 1.35% as of March 31, 2023 and 1.43% as of December 31, 2022.
(2)Variable interest mortgage notes bear variable interest of SOFR + 1.85% and LIBOR + 2.75% for a weighted average interest rate of 6.76% and 6.20% as of March 31, 2023 and December 31, 2022, respectively. The notes are due in 2026 and 2028 and collateralized by four properties with a net book value of $291.1 million as of March 31, 2023 and $295.5 million as of December 31, 2022.
(3)The unsecured revolving credit facility bears variable interest of SOFR plus 0.95%, inclusive of a 0.10% SOFR index adjustment, as of March 31, 2023 and LIBOR plus 0.85% as of December 31, 2022.
On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Third Amended and Restated Credit Agreement (the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The
13
Credit Agreement includes an unsecured revolving credit facility of $1.0 billion and contains a term loan feature of $250.0 million, which the Company borrowed on, bringing total borrowing capacity to $1.25 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. On October 13, 2021, the Company paid off the $250.0 million term loan feature of the Credit Agreement and the term loan feature is no longer available to the Company. The revolving credit facility under the Credit Agreement also includes two six-month extension options. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement.
On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Credit Agreement which expanded the accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, resulting in a maximum borrowing capacity of $2.25 billion, and replaced the LIBOR-based benchmark rates applicable to borrowings under the Credit Agreement with SOFR based benchmark rates plus a SOFR index adjustment of 0.10%.
As of March 31, 2023, the Trust had investment grade ratings of BBB from S&P and Baa2 from Moody’s. As such, borrowings under the revolving credit facility of the Credit Agreement accrue interest on the outstanding principal at a rate of SOFR + 0.95%, inclusive of a 0.10% SOFR index adjustment. The Credit Agreement includes a facility fee equal to 0.20% per annum, which is also determined by the Trust’s investment grade rating.
Base Rate Loans, Adjusted SOFR Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:
| Credit Rating | Applicable Margin for Revolving Loans: SOFR Loans and Letter of Credit Fee | Applicable Margin for Revolving Loans: Base Rate Loans | Applicable Margin for Term Loans: SOFR Loans | Applicable Margin for Term Loans: Base Rate Loans | ||||||||||||||||||||||
| At Least A- or A3 | SOFR + 0.725% | — | % | SOFR + 0.85% | — | % | ||||||||||||||||||||
| At Least BBB+ or Baa1 | SOFR + 0.775% | — | % | SOFR + 0.90% | — | % | ||||||||||||||||||||
| At Least BBB or Baa2 | SOFR + 0.85% | — | % | SOFR + 1.00% | — | % | ||||||||||||||||||||
| At Least BBB- or Baa3 | SOFR + 1.05% | 0.05 | % | SOFR + 1.25% | 0.25 | % | ||||||||||||||||||||
| Below BBB- or Baa3 | SOFR + 1.40% | 0.40 | % | SOFR + 1.65% | 0.65 | % | ||||||||||||||||||||
The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt, grant liens, or make distributions. The Company may, at any time, voluntarily prepay any revolving or term loan under the Credit Agreement in whole or in part without premium or penalty. As of March 31, 2023, the Company was in compliance with all financial covenants related to the Credit Agreement.
The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.
As of March 31, 2023, the Company had $152.0 million of borrowings outstanding under its unsecured revolving credit facility. As defined by the Credit Agreement, the current unencumbered borrowing base allows the Company to borrow an additional $848.0 million before reaching the maximum allowed under the credit facility.
Notes Payable
As of March 31, 2023, the Company had $1.5 billion aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $545.0 million maturing in 2031.
Certain properties have mortgage debt that contains financial covenants. As of March 31, 2023, the Trust was in compliance with all mortgage debt financial covenants.
14
Scheduled principal payments due on consolidated debt as of March 31, 2023 are as follows (in thousands):
| 2023 | $ | 754 | |||
| 2024 | 59,719 | ||||
| 2025 | 177,476 | ||||
| 2026 | 170,476 | ||||
| 2027 | 425,476 | ||||
| Thereafter | 942,775 | ||||
| Total Payments | $ | 1,776,676 | |||
As of March 31, 2023, the Company had total consolidated indebtedness of approximately $1.8 billion. The weighted average interest rate on consolidated indebtedness was 4.03% (based on the 30-day LIBOR rate of 4.77% and a SOFR rate of 4.87% as of March 31, 2023).
For the three months ended March 31, 2023 and 2022, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of $18.6 million and $16.2 million, respectively.
Note 7. Derivatives
In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.
When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings.
To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2023, the Company had one outstanding interest rate swap contract designated as a cash flow hedge of interest rate risk. See Note 2 (Summary of Significant Accounting Policies) of the 2022 Annual Report for a further discussion of our derivatives. In addition, the Company recognizes its share of other comprehensive income related to derivative instruments held by unconsolidated entities.
The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):
| Total notional amount | $ | 36,050 | ||||||
| Effective fixed interest rate | (1) | 3.25 | % | |||||
| Effective date | 10/31/2019 | |||||||
| Maturity date | 10/31/2024 | |||||||
Asset balance at March 31, 2023 (included in Other assets) | $ | 1,645 | ||||||
Asset balance at December 31, 2022 (included in Other assets) | $ | 2,045 | ||||||
(1)1.35% effective swap rate plus 1.90% spread per hedging agreement.
15
Note 8. Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
| March 31, 2023 | December 31, 2022 | ||||||||||
| Prepaid rent | $ | 29,041 | $ | 21,062 | |||||||
| Real estate taxes payable | 18,982 | 23,303 | |||||||||
| Accrued interest | 11,540 | 18,196 | |||||||||
| Accrued expenses | 8,524 | 7,920 | |||||||||
| Security deposits | 4,382 | 4,338 | |||||||||
| Accrued incentive compensation | 1,579 | 2,700 | |||||||||
| Tenant improvement allowances | 1,401 | 1,831 | |||||||||
| Other | 9,558 | 8,370 | |||||||||
| Total | $ | 85,007 | $ | 87,720 | |||||||
Note 9. Stock-based Compensation
The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.
Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available.
In connection with the IPO, the Trust adopted the Physicians Realty Trust 2013 Equity Incentive Plan, which made shares available for awards for participants. On April 30, 2019, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved the Amended and Restated Physicians Realty Trust 2013 Equity Incentive Plan (“2013 Plan”). The amendment increased the number of common shares authorized for issuance under the 2013 Plan to a total of 7,000,000 common shares authorized for issuance. The 2013 Plan term was also extended to 2029.
Restricted Common Shares
Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. In the three months ended March 31, 2023, the Trust granted a total of 291,324 restricted common shares with a total value of $4.3 million to its officers and certain of its employees. In January 2023, under the 2013 Plan, the Company granted restricted common shares to certain of its officers under a salary deferral program, part of which vests after one year, with the remainder vesting after two years. The remaining awards have a vesting period of one year.
16
A summary of the status of the Trust’s non-vested restricted common shares as of March 31, 2023 and changes during the three month period then ended follow:
| Common Shares | Weighted Average Grant Date Fair Value | ||||||||||
| Non-vested at December 31, 2022 | 272,898 | $ | 16.69 | ||||||||
| Granted | 291,324 | 14.67 | |||||||||
| Vested | (210,380) | 16.37 | |||||||||
| Forfeited | (364) | 17.45 | |||||||||
| Non-vested at March 31, 2023 | 353,478 | $ | 15.21 | ||||||||
For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the three months ended March 31, 2023 and 2022, the Company recognized non-cash share compensation of $1.1 million and $0.9 million, respectively. Unrecognized compensation expense at March 31, 2023 was $4.5 million.
Restricted Share Units
In January 2023, under the 2013 Plan, the Company granted 11,274 restricted share units to certain of its trustees in lieu of all or a portion of such trustee’s 2023 cash retainer. These units are subject to certain timing conditions and a one-year service period. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. With respect to the performance and timing conditions of the January 2023 grants, the grant date fair value of $14.47 per unit was based on the share price at the date of grant.
In March 2023, under the 2013 Plan, the Company granted restricted share units at a target level of 355,388 to its officers and certain of its employees and 62,586 to its trustees. Units granted to officers and certain employees under the Company’s 2013 Plan are subject to certain performance and market conditions and a three-year service period. Units granted to trustees are subject to certain timing conditions and a two-year service period for full vesting. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.
Approximately 30% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan in 2023 vest based on a certain market condition. The awards containing the market condition were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $18.71 per unit for the March 2023 grant using the following assumptions:
| Volatility | 23.4 | % | |||
| Dividend assumption | reinvested | ||||
| Expected term in years | 2.83 years | ||||
| Risk-free rate | 4.70 | % | |||
| Share price (per share) | $ | 14.70 | |||
The remaining 70% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan, and 100% of other restricted share units issued to trustees vest based upon certain performance or timing conditions. With respect to the performance and timing conditions of the March 2023 grants, the grant date fair value of $14.70 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2023 restricted share units issued to officers and certain employees was $15.90 per unit.
17
The following is a summary of the activity in the Trust’s restricted share units during the three months ended March 31, 2023:
| Executive Awards | Trustee Awards | ||||||||||||||||||||||
| Restricted Share Units | Weighted Average Grant Date Fair Value | Restricted Share Units | Weighted Average Grant Date Fair Value | ||||||||||||||||||||
| Non-vested at December 31, 2022 | 1,046,940 | $ | 21.41 | 77,992 | $ | 16.60 | |||||||||||||||||
| Granted | 355,388 | 15.90 | 73,860 | 14.66 | |||||||||||||||||||
| Vested | (223,579) | (1) | 24.36 | (49,890) | 16.74 | ||||||||||||||||||
| Non-vested at March 31, 2023 | 1,178,749 | $ | 19.19 | 101,962 | $ | 15.13 | |||||||||||||||||
(1)Restricted units vested by Company executives in 2023 resulted in the issuance of 652,851 common shares, less 290,380 common shares withheld to cover minimum withholding tax obligations.
For the three months ended March 31, 2023 and 2022, the Company recognized non-cash share compensation of $3.5 million and $3.3 million, respectively. Unrecognized compensation expense at March 31, 2023 was $16.3 million.
Note 10. Fair Value Measurements
ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.
In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. As part of the Company’s acquisition process, Level 3 inputs are used to measure the fair value of the assets acquired and liabilities assumed.
The Company’s derivative instruments as of March 31, 2023 consist of one interest rate swap, as detailed in the Derivative Instruments section of Note 7 (Derivatives) of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2022 Annual Report.
The interest rate swap is not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.
The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no such assets measured at fair value as of March 31, 2023.
The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.
18
The following table presents the fair value of the Company’s financial instruments (in thousands):
| March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
| Carrying Amount | Fair Value | Carrying Amount | Fair Value | ||||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Real estate loans receivable, net | $ | 115,764 | $ | 113,453 | $ | 104,973 | $ | 102,162 | |||||||||||||||
| Notes receivable, net | $ | 367 | $ | 367 | $ | 370 | $ | 370 | |||||||||||||||
| Derivative assets | $ | 1,645 | $ | 1,645 | $ | 2,045 | $ | 2,045 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Credit facility | $ | (152,000) | $ | (152,000) | $ | (193,000) | $ | (193,000) | |||||||||||||||
| Notes payable | $ | (1,460,000) | $ | (1,307,272) | $ | (1,475,000) | $ | (1,302,767) | |||||||||||||||
| Mortgage debt | $ | (164,676) | $ | (163,429) | $ | (164,929) | $ | (163,129) | |||||||||||||||
Note 11. Tenant Operating Leases
The Company is a lessor of medical office buildings and other health care facilities. Leases have expirations from 2023 through 2042. As of March 31, 2023, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for assets classified as held for sale, if applicable, were as follows (in thousands):
| 2023 | $ | 270,431 | |||
| 2024 | 352,374 | ||||
| 2025 | 334,894 | ||||
| 2026 | 278,001 | ||||
| 2027 | 226,004 | ||||
| Thereafter | 764,694 | ||||
| Total | $ | 2,226,398 | |||
For the three months ended March 31, 2023 and 2022, the Company recognized $131.4 million and $127.8 million, respectively, of rental and other lease-related income related to our operating leases, of which $37.9 million and $35.1 million, respectively, were variable lease payments.
Note 12. Rent Expense
The Company leases the rights to parking structures at two of its properties, the air that one property occupies, and the land upon which 97 of its properties are located from third party landowners pursuant to separate leases. In addition, the Company has nine corporate leases, primarily for office space.
The Company’s leases include both fixed and variable rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 93 years remaining, excluding extension options, with a weighted average remaining term of 44 years.
At the inception of a new lease, the Company establishes an operating or finance lease asset and operating or finance lease liability calculated as the present value of future minimum lease payments. As our leases do not provide an implicit rate, we calculate a discount rate that approximates our incremental borrowing rate available at lease commencement to determine the present value of future minimum lease payments. The approximated weighted average discount rate was 4.4% as of March 31, 2023. There are no operating or finance leases that have not yet commenced that would have a significant impact on the Company’s consolidated balance sheets.
19
As of March 31, 2023, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases were as follows (in thousands):
| 2023 | $ | 3,539 | |||
| 2024 | 4,819 | ||||
| 2025 | 4,798 | ||||
| 2026 | 4,787 | ||||
| 2027 | 4,789 | ||||
| Thereafter | 239,130 | ||||
| Total undiscounted lease payments | $ | 261,862 | |||
| Less: Interest | (157,006) | ||||
| Present value of lease liabilities | $ | 104,856 | |||
Lease costs consisted of the following for the three months ended March 31, 2023 (in thousands):
| Fixed lease cost | $ | 817 | |||
| Variable lease cost | 338 | ||||
| Total lease cost | $ | 1,155 | |||
Note 13. Credit Concentration
The Company uses annualized base rent (“ABR”) as its credit concentration metric. ABR is calculated by multiplying contractual base rent for the month ended March 31, 2023 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of March 31, 2023 (in thousands):
| Tenant | Total ABR | Percent of ABR | ||||||||||||
| CommonSpirit - CHI - Nebraska | $ | 18,142 | 5.0 | % | ||||||||||
| Northside Hospital | 16,238 | 4.5 | % | |||||||||||
| UofL Health - Louisville, Inc. | 14,373 | 4.0 | % | |||||||||||
| US Oncology | 11,443 | 3.2 | % | |||||||||||
| HonorHealth | 11,220 | 3.1 | % | |||||||||||
| Remaining portfolio | 289,558 | 80.2 | % | |||||||||||
| Total | $ | 360,974 | 100.0 | % | ||||||||||
ABR collected from the Company’s top five tenant relationships comprises 19.8% of its total ABR as of March 31, 2023. Total ABR from CommonSpirit-affiliated tenants totals 14.8%, including the affiliates disclosed above.
The following table summarizes certain information about the Company’s top five geographic concentrations as of March 31, 2023:
| State | Total ABR | Percent of ABR | ||||||||||||
| Texas | $ | 49,397 | 13.7 | % | ||||||||||
| Georgia | 26,570 | 7.4 | % | |||||||||||
| Florida | 25,512 | 7.1 | % | |||||||||||
| Indiana | 23,379 | 6.5 | % | |||||||||||
| Arizona | 21,542 | 6.0 | % | |||||||||||
| Other | 214,574 | 59.3 | % | |||||||||||
| Total | $ | 360,974 | 100.0 | % | ||||||||||
20
Note 14. Earnings Per Share
The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
Numerator for earnings per share - basic: | |||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Net income attributable to noncontrolling interests: | |||||||||||
| Operating Partnership | (423) | (692) | |||||||||
| Partially owned properties | (44) | (159) | |||||||||
| Numerator for earnings per share - basic | $ | 10,202 | $ | 13,092 | |||||||
| Numerator for earnings per share - diluted: | |||||||||||
| Numerator for earnings per share - basic | $ | 10,202 | $ | 13,092 | |||||||
| Noncontrolling interest - Operating Partnership income | 423 | 692 | |||||||||
| Numerator for earnings per share - diluted | $ | 10,625 | $ | 13,784 | |||||||
Denominator for earnings per share - basic and diluted: | |||||||||||
| Weighted average number of shares outstanding - basic | 237,484,043 | 225,069,208 | |||||||||
| Effect of dilutive securities: | |||||||||||
| Noncontrolling interest - Operating Partnership units | 9,842,219 | 11,912,099 | |||||||||
| Restricted common shares | 130,172 | 104,910 | |||||||||
| Restricted share units | 1,300,238 | 1,254,026 | |||||||||
| Denominator for earnings per share - diluted: | 248,756,672 | 238,340,243 | |||||||||
| Earnings per share - basic | $ | 0.04 | $ | 0.06 | |||||||
| Earnings per share - diluted | $ | 0.04 | $ | 0.06 | |||||||
Note 15. Subsequent Events
Since March 31, 2023, the Company completed the acquisition of two medical condominium units located in an Atlanta “Pill Hill” medical office building (“MOB”) for an aggregate purchase price of approximately $1.4 million and funded additional costs of $0.8 million related to our development project.
The Company also contributed $2.0 million to our existing Davis Joint Venture for our pro-rata share of two earn-out agreements. Additionally, we funded a $3.4 million term loan with the Davis Joint Venture related to these earn-out agreements.
21
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our unaudited consolidated financial statements, including the notes to those statements, included in Part I, Item 1 of this report, and the Section entitled “Cautionary Statement Regarding Forward-Looking Statements” in this report. As discussed in more detail in the Section entitled “Cautionary Statement Regarding Forward-Looking Statements,” this discussion contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause those differences include those discussed in Part I, Item 1 (Business) and Part I, Item 1A (Risk Factors) of our 2022 Annual Report.
First Quarter Highlights:
•Reported first quarter 2023 total revenue of $134.3 million, an increase of 3.0% over the prior year period.
•Reported net income of $10.7 million for the first quarter ended 2023, a decrease of 23.5% over the prior year period, and first quarter net income per share of $0.04 on a fully diluted basis.
•Generated first quarter Normalized Funds From Operations (“Normalized FFO”) of $0.24 per share on a fully diluted basis.
•Completed $14.4 million in investments, including the funding of previous loan commitments in the first quarter.
•Executed contractual commitments of a $40.5 million development located in the Atlanta MSA.
•First quarter MOB Same-Store Cash Net Operating Income growth was 1.0% year-over-year.
•Declared a quarterly dividend of $0.23 per share and OP Unit for the first quarter 2023, paid on April 18, 2023.
•Disposed of a 30,000 square foot medical office building on January 17, 2023 for $2.6 million, recognizing an insignificant net gain on the sale.
•Sold 4,400,000 common shares pursuant to the ATM Program at a weighted average price of $15.10 during the first quarter, resulting in net proceeds of $65.8 million.
Overview
We are a self-managed health care real estate company organized in April 2013 to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems. We invest in real estate that is integral to providing high quality health care services. Our properties are typically located on a campus with a hospital or other health care facilities or strategically affiliated with a hospital or other health care facilities. We believe the impact of government programs and continuing trends in the health care industry create attractive opportunities for us to invest in health care related real estate. In particular, we believe the demand for health care will continue to increase as a result of the aging population as older persons generally utilize health care services at a rate well in excess of younger people. Our management team has significant public health care REIT experience and has long-established relationships with physicians, hospitals, and health care delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical office buildings, outpatient treatment facilities, as well as other real estate integral to health care providers. In recent years, we have seen increased competition for health care properties and we expect this trend to continue. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.
We grew our portfolio of gross real estate investments from approximately $124 million at the time of our IPO in July 2013 to approximately $5.8 billion as of March 31, 2023. As of March 31, 2023, our consolidated portfolio consisted of 275 health care properties located in 32 states with approximately 15,516,476 net leasable square feet, which were approximately 95% leased with a weighted average remaining lease term of approximately 5.5 years. As of March 31, 2023, approximately 91% of the net leasable square footage of our portfolio was either on the campus of a hospital or strategically affiliated with a health system.
We receive a cash rental stream from the health care providers under our leases. Approximately 93% of the annualized base rent payments from our properties as of March 31, 2023 were from absolute net and triple net leases, pursuant to which the tenants are responsible for operating expenses subject to specific lease terms relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides more predictable cash flow. Approximately 6% of the ABR payments from our properties as of March 31, 2023 were from modified gross leases which allow us to pass through certain increases in future operating expenses (e.g., property tax and insurance) to tenants for reimbursement, thus protecting us from increases in such operating expenses.
22
We seek to structure our triple-net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 4.0%, with an annual weighted average rent escalator of approximately 2.4%. However, certain of the Company’s leases contain annual rent escalators indexed to changes in the Consumer Price Index (“CPI”), often with a floor or ceiling. As of March 31, 2023, approximately 5.8% of the Company’s annual rent escalators had CPI provisions. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other health care facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases. As of March 31, 2023, leases representing approximately 3.1%, 5.5%, and 7.0% of leased square feet will expire in 2023, 2024, and 2025, respectively.
We intend to grow our portfolio of high-quality health care properties leased to physicians, hospitals, health care delivery systems, and other health care providers primarily through acquisitions of existing health care facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new health care facilities through joint venture or fee arrangements with health care real estate developers or health system development professionals. Generally, we expect to make investments in new development properties when approximately 80% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound health care providers and health care delivery systems that offer need-based health care services in sustainable health care markets. We focus our investment activity on medical office buildings and ambulatory surgery centers.
We believe that trends such as shifting consumer preferences, limited space in hospitals, the desire of patients and health care providers to limit non-essential services provided in a hospital setting, and cost considerations, continue to drive the industry towards performing more procedures in outpatient facilities versus the hospital setting. As these trends continue, we believe that demand for medical office buildings and similar health care properties away from hospital settings and in convenient locations to patients will continue to rise. We intend to exploit this trend and seek outpatient properties consistent with our investment philosophy and strategies.
While not our focus, we may choose to invest opportunistically in life science facilities, senior housing properties, skilled nursing facilities, specialty hospitals, and treatment centers. Consistent with our qualification as a REIT, we may also opportunistically invest in companies that provide health care services, and in joint venture entities with operating partners, structured to comply with the REIT Investment Diversification Act of 2007.
The Trust is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an UPREIT structure in which our properties are owned by our Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of our Operating Partnership and, as of March 31, 2023, owned approximately 96.0% of the OP Units. As of April 26, 2023, there were 238,398,561 common shares outstanding.
Key Transactions in First Quarter 2023
Investment Activity
During the three months ended March 31, 2023, the Company executed contractual commitments related to a $40.5 million development project, with quarterly costs of $1.0 million, completed the acquisition of one medical condominium unit for an investment of $1.3 million and one parcel of land adjacent to one of its medical office facilities for an investment of $0.8 million, and paid $0.3 million of additional purchase consideration under two earn-out agreements. The Company also closed on a $35.8 million construction loan, funding $4.1 million to date, and funded one term loan for $5.4 million, $1.0 million of previous construction loan commitments, and $0.5 million of previous term loan commitments. Additionally, the Company invested $0.2 million in funds managed by a real estate technology private equity fund. Investment activity for the three months ended March 31, 2023 totaled approximately $14.4 million.
During the three months ended March 31, 2023, the Company sold one 30,000 square foot medical facility for approximately $2.6 million, realizing an insignificant net gain.
23
Recent Developments
Quarterly Distribution
On March 17, 2023, we announced that our Board of Trustees authorized and declared a cash distribution of $0.23 per common share for the quarterly period ended March 31, 2023. The dividend was paid on April 18, 2023 to common shareholders and OP Unit holders of record as of the close of business on April 4, 2023.
Recent Events
Since March 31, 2023, the Company completed the acquisition of two medical condominium units located in an Atlanta “Pill Hill” MOB for an aggregate purchase price of approximately $1.4 million and funded additional costs of $0.8 million related to our development project.
The Company also contributed $2.0 million to our existing Davis Joint Venture for our pro-rata share of two earn-out agreements. Additionally, we funded a $3.4 million term loan with the Davis Joint Venture related to these earn-out agreements.
Results of Operations
Three months ended March 31, 2023 compared to the three months ended March 31, 2022.
The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022 (in thousands):
| 2023 | 2022 | Change | % | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Rental and related revenues | $ | 131,398 | $ | 127,791 | $ | 3,607 | 2.8 | % | |||||||||||||||
| Interest income on real estate loans and other | 2,946 | 2,599 | 347 | 13.4 | % | ||||||||||||||||||
| Total revenues | 134,344 | 130,390 | 3,954 | 3.0 | % | ||||||||||||||||||
| Expenses: | |||||||||||||||||||||||
| Interest expense | 19,153 | 16,823 | 2,330 | 13.9 | % | ||||||||||||||||||
| General and administrative | 11,200 | 10,293 | 907 | 8.8 | % | ||||||||||||||||||
| Operating expenses | 45,394 | 41,752 | 3,642 | 8.7 | % | ||||||||||||||||||
| Depreciation and amortization | 47,677 | 47,260 | 417 | 0.9 | % | ||||||||||||||||||
| Total expenses | 123,424 | 116,128 | 7,296 | 6.3 | % | ||||||||||||||||||
| Income before equity in loss of unconsolidated entities and gain (loss) on sale of investment properties, net: | 10,920 | 14,262 | (3,342) | (23.4) | % | ||||||||||||||||||
| Equity in loss of unconsolidated entities | (264) | (166) | (98) | NM | |||||||||||||||||||
| Gain (loss) on sale of investment properties, net | 13 | (153) | 166 | NM | |||||||||||||||||||
| Net income | $ | 10,669 | $ | 13,943 | $ | (3,274) | (23.5) | % | |||||||||||||||
NM = Not Meaningful
Revenues
Total revenues increased $4.0 million, or 3.0%, for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. An analysis of selected revenues follows.
Rental and related revenues. Rental and related revenues increased $3.6 million, or 2.8%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Rental and related revenues were comprised of the following based upon contractual billing terms (in thousands):
24
| 2023 | 2022 | Change | % | ||||||||||||||||||||
| Rental revenues | $ | 93,543 | $ | 92,665 | $ | 878 | 0.9 | % | |||||||||||||||
| Expense recoveries | 37,855 | 35,126 | 2,729 | 7.8 | % | ||||||||||||||||||
| Rental and related revenues | $ | 131,398 | $ | 127,791 | $ | 3,607 | 2.8 | % | |||||||||||||||
Rental revenues increased $0.9 million, or 0.9%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Rental revenues increased $1.7 million from properties acquired in 2022 and $0.7 million related to net increases on our existing portfolio. These increases were partially offset by a decrease of $1.5 million related to properties sold in 2022.
Expense recoveries increased $2.7 million, or 7.8%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Expense recoveries increased $2.0 million related to net increases on our existing portfolio and $0.8 million from properties acquired in 2022.
Interest income on real estate loans and other. Interest income on real estate loans and other increased $0.3 million, or 13.4%, for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Interest income on real estate loans and other increased $0.2 million due to property management income related to the management for our unconsolidated joint ventures and $0.1 million due to higher average real estate loan balances in 2023 compared to 2022.
Expenses
Total expenses increased $7.3 million, or 6.3%, for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. An analysis of selected expenses follows.
Interest expense. Interest expense increased $2.3 million, or 13.9%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Interest expense increased primarily due to a higher weighted average effective interest rate on our credit facility by $2.0 million and higher interest on our existing variable mortgage debts of $0.8 million. Our weighted average effective interest rate on our credit facility was 5.4% and 1.0% for the three months ended March 31, 2023 and 2022, respectively, and our weighted average effective interest rate on our variable mortgage debt was 6.8% and 2.2% for the three months ended March 31, 2023 and 2022, respectively. These increases were partially offset by $0.4 million of net proceeds from the Company’s outstanding interest rate swap.
General and administrative. General and administrative expenses increased $0.9 million, or 8.8%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The increase was primarily due to higher payroll and benefits of $0.6 million, of which $0.4 million was non-cash compensation, and $0.3 million of administrative and professional fees.
Operating expenses. Operating expenses increased $3.6 million, or 8.7%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Net operating expenses from properties acquired in 2022 increased by $0.8 million. Operating expenses on the existing portfolio increased by $2.8 million, or 6.7% quarter over quarter, mainly due to higher maintenance costs of $1.3 million, utility costs of $1.0 million, and property management costs of $0.5 million.
Depreciation and amortization. Depreciation and amortization increased $0.4 million, or 0.9%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Depreciation and amortization increased $1.2 million for properties purchased in 2022. These increases were partially offset by $0.5 million related to properties sold during 2022 and $0.2 million related to our existing portfolio primarily due to fully amortized lease intangibles.
Equity in loss of unconsolidated entities. The change in equity in loss of unconsolidated entities for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 is insignificant.
Gain (loss) on sale of investment properties, net. During the three months ended March 31, 2023, we sold one property in Pennsylvania, containing 30,000 square feet for approximately $2.6 million, realizing an insignificant gain. During the three months ended March 31, 2022, we sold one property containing 9,997 net leasable square feet located in Michigan for approximately $2.0 million, realizing an insignificant net loss.
25
Cash Flows
Three months ended March 31, 2023 compared to the three months ended March 31, 2022 (in thousands).
| 2023 | 2022 | ||||||||||
| Cash provided by operating activities | $ | 63,719 | $ | 54,535 | |||||||
| Cash (used in) provided by investing activities | (21,768) | 12,181 | |||||||||
| Cash used in financing activities | (46,317) | (73,863) | |||||||||
| Decrease in cash and cash equivalents | $ | (4,366) | $ | (7,147) | |||||||
Cash flows from operating activities. Cash flows provided by operating activities was $63.7 million during the three months ended March 31, 2023 compared to $54.5 million during the three months ended March 31, 2022, representing an increase of $9.2 million. The increase in cash provided by operating activities is primarily due the timing of our payments on accounts payable and other liabilities.
Cash flows from investing activities. Cash flows used in investing activities was $21.8 million during the three months ended March 31, 2023 compared to cash flows provided by investing activities of $12.2 million during the three months ended March 31, 2022, representing a change of $33.9 million. The change in cash used in investing activities was primarily due to a decrease in repayment of real estate loans receivables of $22.4 million and an increase of $10.1 million from cash used in the investment of real estate loan receivables. Additionally, cash spent on capital expenditures and lease inducements increased by $2.9 million and $0.4 million, respectively. This was partially offset by a net decrease of $1.2 million of cash spent on development and acquisitions of investment properties and unconsolidated entities. Further, there was an increase of $0.7 million from the proceeds on sales of investment properties.
Cash flows from financing activities. Cash flows used in financing activities was $46.3 million during the three months ended March 31, 2023 compared to $73.9 million during the three months ended March 31, 2022, representing a decrease of $27.5 million. The decrease in cash used in financing activities was primarily due to an increase in net proceeds from the sale of common shares pursuant to the ATM Program of $60.8 million and an increase of $7.3 million from contributions from noncontrolling interests. Additionally, cash used in financing activities decreased due to a decrease of distributions to noncontrolling interests of $0.5 million, a decrease in purchases of OP units of $0.2 million and a decrease in principal payments on mortgage debt of $0.2 million. This is partially offset by an increase of $22.0 million in net paydowns under the credit facility and $15.0 million from the repayment of senior unsecured notes. Further, there was an increase of dividends paid to shareholders of $2.8 million and an increase of $1.7 million for payments of employee taxes withheld for stock-based compensation.
Non-GAAP Financial Measures
This report includes Funds From Operations (“FFO”), Normalized FFO, Normalized Funds Available For Distribution (“FAD”), Net Operating Income (“NOI”), Cash NOI, MOB Same-Store Cash NOI, Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (“EBITDAre”) and Adjusted EBITDAre, which are non-GAAP financial measures. For purposes of Item 10(e) of Regulation S-K promulgated under the Securities Act, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this report, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Item 10(e) of Regulation S-K promulgated under the Securities Act, we have provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
26
FFO and Normalized FFO
We believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. We calculate FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (“Nareit”). Nareit defines FFO as net income or loss (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding preferred distributions, gains (or losses) on sales of depreciable operating property, impairment write-downs on depreciable assets, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation includes our share of required adjustments from our unconsolidated joint ventures and may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the Nareit definition or that interpret the Nareit definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income, includes depreciation and amortization expenses, gains or losses on property sales, impairments, and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating results, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income or loss (determined in accordance with GAAP) as a measure of our liquidity and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.
We use Normalized FFO, which excludes from FFO net change in fair value of derivative financial instruments, acceleration of deferred financing costs, net change in fair value of contingent consideration, and other normalizing items. Our Normalized FFO computation includes our share of required adjustments from our unconsolidated joint ventures and our use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss (computed in accordance with GAAP), as an indicator of our financial performance or of cash flow from operating activities (computed in accordance with GAAP), or as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.
The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to FFO and Normalized FFO (in thousands, except per share data):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Earnings per share - diluted | $ | 0.04 | $ | 0.06 | |||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Net income attributable to noncontrolling interests - partially owned properties | (44) | (159) | |||||||||
| Depreciation and amortization expense | 47,560 | 47,149 | |||||||||
| Depreciation and amortization expense - partially owned properties | (138) | (70) | |||||||||
| (Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | 2,306 | 2,383 | |||||||||
| FFO applicable to common shares | $ | 60,340 | $ | 63,399 | |||||||
| Proportionate share of unconsolidated joint venture adjustments | — | (8) | |||||||||
| Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
| FFO per common share - diluted | $ | 0.24 | $ | 0.27 | |||||||
| Normalized FFO per common share - diluted | $ | 0.24 | $ | 0.27 | |||||||
| Weighted average common shares outstanding - diluted | 248,756,672 | 238,340,243 | |||||||||
27
Normalized Funds Available for Distribution (“FAD”)
We define Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO non-cash share compensation expense, straight-line rent adjustments, amortization of acquired above-market or below-market leases and assumed debt, amortization of lease inducements, amortization of deferred financing costs, and loan reserve adjustments, including our share of all required adjustments from unconsolidated joint ventures. We also adjust for recurring capital expenditures related to building, site, and tenant improvements, leasing commissions, cash payments from seller master leases, and rent abatement payments, including our share of all required adjustments for unconsolidated joint ventures. Other REITs or real estate companies may use different methodologies for calculating Normalized FAD, and accordingly, our computation may not be comparable to those reported by other REITs. Although our computation of Normalized FAD may not be comparable to that of other REITs, we believe Normalized FAD provides a meaningful supplemental measure of our performance due to its frequency of use by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) or as an indicator of our financial performance. Normalized FAD should be reviewed in connection with other GAAP measurements.
The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to Normalized FAD (in thousands):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
| Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
| Non-cash share compensation expense | 4,667 | 4,253 | |||||||||
| Straight-line rent adjustments | (1,235) | (2,154) | |||||||||
| Amortization of acquired above/below-market leases/assumed debt | 1,135 | 1,339 | |||||||||
| Amortization of lease inducements | 229 | 225 | |||||||||
| Amortization of deferred financing costs | 569 | 579 | |||||||||
| Recurring capital expenditures and lease commissions | (5,786) | (5,663) | |||||||||
| Loan reserve adjustments | 3 | 3 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | (219) | (431) | |||||||||
| Normalized FAD applicable to common shares | $ | 59,703 | $ | 61,542 | |||||||
Net Operating Income (“NOI”), Cash NOI, and MOB Same-Store Cash NOI
NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, interest expense, net change in the fair value of derivative financial instruments, gain or loss on the sale of investment properties, and impairment losses, including our share of all required adjustments from our unconsolidated joint ventures. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. Our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.
Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired above and below market leases, and other non-cash and normalizing items, including our share of all required adjustments from unconsolidated joint ventures. Other non-cash and normalizing items include items such as the amortization of lease inducements, loan reserve adjustments, payments received from seller master leases and rent abatements, and changes in fair value of contingent consideration. We believe that Cash NOI provides an accurate measure of the operating performance of our operating assets because it excludes certain items that are not associated with management of the properties. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. Our use of the term Cash NOI may not be comparable to that of other real estate companies as such other companies may have different methodologies for computing this amount.
28
MOB Same-Store Cash NOI is a non-GAAP financial measure which excludes from Cash NOI assets not held for the entire preceding five quarters, non-MOB assets, and other normalizing items not specifically related to the same-store property portfolio. Management considers MOB Same-Store Cash NOI a supplemental measure because it allows investors, analysts, and Company management to measure unlevered property-level operating results. Our use of the term MOB Same-Store Cash NOI may not be comparable to that of other real estate companies, as such other companies may have different methodologies for computing this amount.
The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to NOI, Cash NOI, and MOB Same-Store Cash NOI (in thousands):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| General and administrative | 11,200 | 10,293 | |||||||||
| Depreciation and amortization expense | 47,677 | 47,260 | |||||||||
| Interest expense | 19,153 | 16,823 | |||||||||
| (Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | 3,644 | 3,422 | |||||||||
| NOI | $ | 92,330 | $ | 91,894 | |||||||
| NOI | $ | 92,330 | $ | 91,894 | |||||||
| Straight-line rent adjustments | (1,235) | (2,154) | |||||||||
| Amortization of acquired above/below-market leases | 1,135 | 1,349 | |||||||||
| Amortization of lease inducements | 229 | 225 | |||||||||
| Loan reserve adjustments | 3 | 3 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | (108) | (71) | |||||||||
| Cash NOI | $ | 92,354 | $ | 91,246 | |||||||
| Cash NOI | $ | 92,354 | $ | 91,246 | |||||||
| Assets not held for all periods or held for sale | (1,458) | (1,504) | |||||||||
| Non-MOB health care properties | (2,798) | (2,758) | |||||||||
| Lease termination fees | (31) | (4) | |||||||||
| Interest income on real estate loans | (2,282) | (2,199) | |||||||||
| Joint venture and other income | (3,768) | (3,576) | |||||||||
| MOB Same-Store Cash NOI | $ | 82,017 | $ | 81,205 | |||||||
Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (“EBITDAre”) and Adjusted EBITDAre
We calculate EBITDAre in accordance with standards established by Nareit and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, including our share of all required adjustments from unconsolidated joint ventures. We define Adjusted EBITDAre, which excludes from EBITDAre non-cash share compensation expense, non-cash changes in fair value, pursuit costs, non-cash intangible amortization, the pro forma impact of investment activity, and other normalizing items. We consider EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.
29
The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to EBITDAre and Adjusted EBITDAre (in thousands):
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net income | $ | 10,669 | $ | 13,943 | |||||||
| Depreciation and amortization expense | 47,677 | 47,260 | |||||||||
| Interest expense | 19,153 | 16,823 | |||||||||
| (Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | 3,590 | 3,420 | |||||||||
EBITDAre | $ | 81,076 | $ | 81,599 | |||||||
| Non-cash share compensation expense | 4,667 | 4,253 | |||||||||
| Pursuit costs | 63 | 74 | |||||||||
| Non-cash intangible amortization | 1,364 | 1,575 | |||||||||
| Proportionate share of unconsolidated joint venture adjustments | — | (8) | |||||||||
| Pro forma adjustments for investment activity | 89 | 68 | |||||||||
Adjusted EBITDAre | $ | 87,259 | $ | 87,561 | |||||||
Liquidity and Capital Resources
Our short-term liquidity requirements consist primarily of operating and interest expenses and other expenditures directly associated with our properties, including:
•property expenses;
•interest expense and scheduled principal payments on outstanding indebtedness;
•general and administrative expenses; and
•capital expenditures for tenant improvements and leasing commissions.
In addition, we will require funds for future distributions expected to be paid to our common shareholders and OP Unit holders in our Operating Partnership.
As of March 31, 2023, we had a total of $3.4 million of cash and cash equivalents and $848.0 million of near-term availability on our unsecured revolving credit facility. Our primary sources of cash include rent we collect from our tenants, borrowings under our unsecured credit facility, and financings of debt and equity securities. We believe that our existing cash and cash equivalents, cash flow from operating activities, and borrowings available under our unsecured revolving credit facility will be adequate to fund any existing contractual obligations to purchase properties and other obligations through the next year. However, because of the 90% distribution requirement under the REIT tax rules under the Internal Revenue Code, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. We will rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.
Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurring and non-recurring capital expenditures, and scheduled debt maturities. We expect to satisfy our long-term liquidity needs through cash flow from operations, unsecured borrowings, issuances of equity and debt securities, proceeds from select property dispositions and joint venture transactions, and, in connection with acquisitions of additional properties, the issuance of OP Units of our Operating Partnership.
Our ability to access capital in a timely and cost-effective manner is essential to the success of our business strategy as it affects our ability to satisfy existing obligations, including repayment of maturing indebtedness, and to make future investments and acquisitions. Factors such as general market conditions, interest rates, credit ratings on our debt and equity securities, expectations of our potential future earnings and cash distributions, and the market price of our common shares, each
30
of which are beyond our control and vary or fluctuate over time, all impact our access to and cost of capital. In particular, to the extent interest rates continue to rise, we may continue to experience a decline in the trading price of our common shares, which may impact our decision to conduct equity offerings for capital raising purposes. We have experienced and will likely continue to experience higher borrowing costs as interest rates rise, which may also impact our decisions to incur additional indebtedness, or to engage in transactions that we may need to fund through borrowing. We expect to continue to utilize equity and debt financings to support our future growth and investment activity.
We also continuously evaluate opportunities to finance future investments. New investments are generally funded from temporary borrowings under our primary unsecured credit facility and the proceeds from financing transactions such as those discussed above. Our investments generate cash from net operating income and principal payments on loans receivable. Permanent financing for future investments, which generally replaces funds drawn under our primary unsecured credit facility, has historically been provided through a combination of the issuance of debt and equity securities and the incurrence or assumption of secured debt.
We intend to invest in additional properties as suitable opportunities arise and adequate sources of financing are available. We are currently evaluating additional potential investments consistent with the normal course of our business. There can be no assurance as to whether or when any portion of these investments will be completed. Our ability to complete investments is subject to a number of risks and variables, including our ability to negotiate mutually agreeable terms with sellers and our ability to finance the investment. We may not be successful in identifying and consummating suitable acquisitions or investment opportunities, which may impede our growth and negatively affect our results of operations and may result in the use of a significant amount of management’s resources. We expect that future investments in properties will depend on and will be financed by, in whole or in part, our existing cash, borrowings, including under our unsecured revolving credit facility, or the proceeds from additional issuances of equity or debt securities.
We currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.
We currently are in compliance with all debt covenants on our outstanding indebtedness.
Credit Facility
On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed the Credit Agreement which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes an unsecured revolving credit facility of $1.0 billion and contains a term loan feature of $250 million, which the Company borrowed on, bringing total borrowing capacity to $1.25 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. On October 13, 2021, the Company paid off the $250.0 million term loan feature of the Credit Agreement and the term loan feature is no longer available to the Company. The revolving credit facility under the Credit Agreement also includes two six-month extension options.
On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Credit Agreement which expanded the accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, resulting in a maximum borrowing capacity of $2.25 billion, and replaced the LIBOR-based benchmark rates applicable to borrowings under the Amended Credit Agreement with SOFR based benchmark rates.
As of March 31, 2023, the Company had $152.0 million of borrowings outstanding under its unsecured revolving credit facility. As defined by the Credit Agreement, $848.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our credit facility.
31
Senior Notes
As of March 31, 2023, we had $1.5 billion aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $545.0 million maturing in 2031. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our senior notes.
ATM Program
In May 2021, the Company entered into the Sales Agreement, pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million. In accordance with the Sales Agreement, the Trust may offer and sell its common shares through the Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker.
During the quarterly period ended March 31, 2023, the Trust sold 4,400,000 common shares pursuant to the ATM Program, at a weighted average price of $15.10 per share resulting in total net proceeds of approximately $65.8 million. As of March 31, 2023, the Trust has $158.6 million remaining available under the ATM Program.
Dividend Reinvestment and Share Purchase Plan
In December 2014, the Company adopted a Dividend Reinvestment and Share Purchase Plan (“DRIP”). Under the DRIP:
•existing shareholders may purchase additional common shares by reinvesting all or a portion of the dividends paid on their common shares and by making optional cash payments of not less than $50 and up to a maximum of $10,000 per month;
•new investors may join the DRIP by making an initial investment of not less than $1,000 and up to a maximum of $10,000; and
•once enrolled in the DRIP, participants may authorize electronic deductions from their bank account for optional cash payments to purchase additional shares.
The DRIP is administered by our transfer agent, Computershare Trust Company, N.A. Our common shares sold under the DRIP are newly issued or purchased in the open market, as further described in the DRIP. As of March 31, 2023, the Company had issued 218,084 common shares under the DRIP since its inception.
Critical Accounting Policies
Our consolidated financial statements included in Part I, Item 1 of this report are prepared in conformity with GAAP for interim financial information set forth in the ASC, as published by the FASB, which require us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our 2022 Annual Report for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our consolidated financial statements included in Part I, Item 1 of this report.
REIT Qualification Requirements
We are subject to a number of operational and organizational requirements necessary to qualify and maintain our qualification as a REIT. If we fail to qualify as a REIT or fail to remain qualified as a REIT in any taxable year, our income would be subject to federal income tax at regular corporate rates and potentially increased state and local taxes and we could incur substantial tax liabilities which could have an adverse impact upon our results of operations, liquidity, and distributions to our shareholders.
32
Off-Balance Sheet Arrangements
As of March 31, 2023, we have investments in two unconsolidated joint ventures with ownership interests of 45.1% and 12.3%, respectively. The aggregate carrying amount of debt, including both our and our partners’ share, incurred by these ventures was approximately $808.5 million (of which our proportionate share is approximately $144.5 million). See Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2022 Annual Report for the fiscal year ended December 31, 2022 for additional information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Our future income, cash flows, and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We do not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. Our derivative instruments consist of one interest rate swap. See Note 7 (Derivatives) in Part I, Item I of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2022 Annual Report for further detail on our interest rate swap.
Interest rate risk amounts are our management’s estimates and were determined by considering the effect of hypothetical interest rates on our consolidated financial instruments. These analyses do not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of that magnitude, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, these analyses assume no changes in our financial structure.
Fixed Interest Rate Debt
As of March 31, 2023, our consolidated fixed interest rate debt totaled $1.5 billion, which represented 83.5% of our total consolidated debt, excluding the impact of the interest rate swap. We entered into a pay-fixed receive-variable rate swap for $36.1 million of our mortgage debt, fixing the variable component of the borrowing rate to 1.35%, for an all-in fixed rate as of March 31, 2023 of 3.25%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of October 31, 2024.
Assuming the effects of our interest rate swap agreement, our fixed interest rate debt would represent 85.5% of our total consolidated debt. Interest rate fluctuations on our fixed interest rate debt will generally not affect our future earnings or cash flows unless such instruments mature or are otherwise terminated. However, interest rate changes could affect the fair value of our fixed interest rate debt.
As of March 31, 2023, the fair value and the carrying value of our consolidated fixed interest rate debt were approximately $1.4 billion and $1.5 billion, respectively. The fair value estimate of our fixed interest rate debt was estimated using a discounted cash flow analysis utilizing rates we would expect to pay for debt of a similar type and remaining maturity if the loans were originated on March 31, 2023. As we expect to hold our fixed interest rate debt instruments to maturity, based on the underlying structure of the debt instrument, and the amounts due under such instruments are limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that market fluctuations in interest rates, and the resulting change in fair value of our fixed interest rate debt instruments, would have a significant impact on our operating cash flows.
Variable Interest Rate Debt
As of March 31, 2023, our consolidated variable interest rate debt totaled $293.1 million, which represented 16.5% of our total consolidated debt. Assuming the effects of our interest rate swap agreement, our variable interest rate debt would represent 14.5% of our total consolidated debt. Interest rate changes on our variable rate debt could impact our future earnings and cash flows but would not significantly affect the fair value of such debt. As of March 31, 2023, we were exposed to market risks related to fluctuations in interest rates on $257.0 million of consolidated borrowings. Assuming no increase in the amount of our variable rate debt, if LIBOR and SOFR were to change by 100 basis points, interest expense on our variable rate debt as of March 31, 2023 would change by approximately $0.1 million and $2.5 million annually, respectively.
33
Derivative Instruments
As of March 31, 2023, we had one outstanding interest rate swap that was designated as a cash flow hedge of interest rate risk, with a total notional amount of $36.1 million. See Note 7 (Derivatives) within our consolidated financial statements for further detail on our interest rate swap. We are exposed to credit risk of the counterparty to our interest rate swap agreement in the event of non-performance under the terms of the agreements. If we were not able to replace the swap in the event of non-performance by the counterparty, we would be subject to variability of the interest rate on the amount outstanding under our debt that is fixed through the use of the swap.
Indebtedness
As of March 31, 2023, we had total consolidated indebtedness of approximately $1.8 billion. The weighted average interest rate on our consolidated indebtedness was 4.03% (based on the 30-day LIBOR rate of 4.77% and a SOFR rate of 4.87% as of March 31, 2023). As of March 31, 2023, we had approximately $257.0 million, or approximately 14.5%, of our outstanding long-term debt exposed to fluctuations in short-term interest rates. See Note 6 (Debt) to our consolidated financial statements included in Part I, Item 1 to this report for a summary of our indebtedness as of March 31, 2023.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Trust’s management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Trust’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on such evaluation, the Trust’s Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2023, the Trust’s disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Trust’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in the Trust’s system of internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Trust’s internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures and the Trust’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Trust’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
34
PART II. Other Information
Item 1. Legal Proceedings
From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition, or results of operations if determined adversely to us.
Item 1A. Risk Factors
Information on risk factors can be found in Part I, Item 1A (Risk Factors) of our 2022 Annual Report. There have been no material changes from the risk factors previously disclosed in our 2022 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Securities
From time to time the Operating Partnership issues OP Units to the Trust, as required by the Partnership Agreement, to reflect additional issuances of common shares by the Trust and to preserve equitable ownership ratios.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
The following table sets forth information relating to repurchases of our common shares of beneficial interest and OP Units during the three months ended March 31, 2023:
ISSUER PURCHASES OF EQUITY SECURITIES
| Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | ||||||||||||||||||||||
| January 1, 2023 - January 31, 2023 | 167,779 | (1) | $ | 14.42 | N/A | N/A | ||||||||||||||||||||
| February 1, 2023 - February 28, 2023 | 290,380 | (2) | 15.07 | N/A | N/A | |||||||||||||||||||||
| March 1, 2023 - March 31, 2023 | 92,895 | (2) | 14.70 | N/A | N/A | |||||||||||||||||||||
| Total | 551,054 | $ | 14.81 | — | — | |||||||||||||||||||||
(1)Represents OP Units redeemed by holders in exchange for common shares of the Company.
(2)Represents repurchased common shares to satisfy employee withholding tax obligations related to stock-based compensation.
35
Item 6. Exhibits
| Exhibit No. | Description | |||||||
| (1) | ||||||||
| 101.INS | This instance document does not appear in the interactive data file because of XBRL tags are embedded within the inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Extension Schema Document (+) | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (+) | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (+) | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (+) | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document (+) | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||||||
** Filed herewith
(+) Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement for purposes of Section 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.
(1) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on April 3, 2023 (File No. 001-36007).
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PHYSICIANS REALTY TRUST | |||||
| Date: May 4, 2023 | /s/ John T. Thomas | ||||
| John T. Thomas | |||||
| President and Chief Executive Officer | |||||
| (Principal Executive Officer) | |||||
| Date: May 4, 2023 | /s/ Jeffrey N. Theiler | ||||
| Jeffrey N. Theiler | |||||
| Executive Vice President and Chief Financial Officer | |||||
| (Principal Financial Officer) | |||||
37